

**COMPOSITION OF DITERPENIC LABDANES EXTRACTED FROM  
ANDROGRAPHIS PANICULATA, USEFUL FOR THE TREATMENT OF  
AUTOIMMUNE DISEASES, AND ALZHEIMER DISEASE BY  
ACTIVATION OF PPR-GAMMA RECEPTORS**

5

**DESCRIPTION**

10 The main objective of immunopharmacology and biopharmacy, is the continuous search of new therapeutic solutions for treating the symptoms and modify the course of immunological diseases.

**BACKGROUND OF THE INVENTION**

15 Autoimmune diseases are characterized by a spontaneous reaction of the immune system against its own organism. These reactions are caused by the recognition of auto-antigens by the T lymphocytes, which are responsible to trigger humoral (auto-antibodies production) and cellular (increased lymphocytes and macrophages cytotoxic activity) immune responses. Autoimmune diseases include: rheumatoid 20 diseases, psoriasis, systemic dermatomyocytis, multiple sclerosis, lupus erythematosus or exacerbated immune responses by antigens, i.e. asthma, allergies to drugs and food, etc. All these diseases are limiting, chronic, and in some cases lethal, and no effective therapy exists nowadays to treat them. Therefore, any drug, medicine, or media that is able to cause remission or decrease in the course of the disease, represents a 25 significant solution for the patients health.

The search for a treatment for autoimmune diseases has resulted in an important effort to find suitable drugs and methods.

At present, the treatment of these diseases is principally based in the use of immunosuppressant drugs, such as glucocorticoids, calcineurin inhibitors, and 5 antiproliferatives-antimetabolites. However, since these pharmacological therapies act in many different targets, they can reduce the immune function as a whole, or due to long term use can have the disadvantage of different cytotoxic effects, and therefore can suppress the immune system in a non specific way, exposing the patient to the 10 risk of infections and cancer. Calcineurin and glucocorticoids exhibit an additional disadvantage, due to their nephrotoxicity and diabetogenic effects, that limits their utility in several clinical conditions (e.g. renal insufficiency, diabetes).

The latest therapeutic advances in immuno-suppression are the anti CD3 monoclonal antibodies; the anti IL-2 receptor monoclonal antibodies and the anti-TNF $\alpha$  15 monoclonal antibodies. Despite the fact that these treatments exhibit marked immunosuppressing effects, anaphylaxis reactions, opportunistic infections (Tuberculosis) and neoplasm's, fever, urticaria, hypotension, dyspnea are associated with these medicines, representing a serious problem in the application of said 20 compositions and pharmaceutical products. In injectable applications, one out of three patient can present itching, swelling, and pain.

## **BRIEF SUMMARY OF THE INVENTION**

The composition claimed in the present invention, is able to diminish the immune 25 response, which characterizes autoimmune diseases, allergies, alleviating the symptoms and the course of the disease, with maintenance of the "immunological tolerance".

In other words, the composition disclosed in the present invention, is essentially characterized according to the immunological tolerance originated by it, which corresponds to the active state of the absence of a specific reaction against an antigen, without causing the side effects of the current immunosuppressant drugs.

5

Specifically, this composition inhibits the synthesis and expression of interferon gamma, IL-2 by stimulating the PPAR gamma receptor and reducing the NF kappaB factor.

10 Consequently, this new composition of diterpenic labdanes is characterized by selectively reducing the cytokines over-expression, which is involved in the pathogenesis of autoimmune diseases.

Recent advances in scientific understanding of the mediators involved in acute and 15 chronic inflammatory diseases and cancer have led to new strategies in the search for effective therapeutics. Traditional approaches include direct target intervention such as the use of specific antibodies, receptor antagonists, or enzyme inhibitors having all of them an important level of side effects (e.g. allergies, gastrointestinal ulcers, bleedings, etc.). Recent breakthroughs in the elucidation of regulatory mechanisms 20 involved in the transcription and translation of a variety of mediators have led to increased interest in therapeutic approaches directed at the level of gene transcription (e.g. COX2, iNOS, IL1beta, TNFalpha, ICAM, etc.).

One of the most important mediators is NF-kappaB that belongs to a family of closely 25 related dimeric transcription factor complexes composed of various combinations of the Rel/NF-kappaB family of polypeptides. The family consists of five individual gene products in mammals, RelA (p65), NF-kappaB1 (p50/p105), NF-kappaB2

(p49/p100), c-Rel, and RelB, all of which can form hetero- or homodimers. These proteins share a highly homologous 300 amino acid "Rel homology domain" which contains the DNA binding and dimerization domains. At the extreme C-terminus of the Rel homology domain is a nuclear translocation sequence important in the 5 transport of NF-kappaB from the cytoplasm to the nucleus. In addition, p65 and cRel possess potent trans-activation domains at their C-terminal ends.

The activity of NF-kappaB is regulated by its interaction with a member of the inhibitor IkappaB family of proteins. This interaction effectively blocks the nuclear 10 localization sequence on the NF-kappaB proteins, thus preventing migration of the dimer to the nucleus. A wide variety of stimuli activate NF-kappaB through what are likely to be multiple signal transduction pathways. Included are bacterial products (LPS), some viruses (HIV-1, HTLV-1), inflammatory cytokines (TNFalpha, IL-1), and environmental stress. Apparently common to all stimuli however, is the 15 phosphorylation and subsequent degradation of IkappaB. IkappaB is phosphorylated on two N-terminal serines by the recently identified IkappaB kinases (*IKK*-alpha and *IKK*-beta). Site-directed mutagenesis studies indicate that these phosphorylations are critical for the subsequent activation of NF-kappaB in that once phosphorylated the protein is flagged for degradation via the ubiquitin-proteasome pathway. Free from 20 IkappaB, the active NF-kappaB complexes are able to translocate to the nucleus where they bind in a selective manner to preferred gene-specific enhancer sequences. Included in the genes regulated by NF-kappaB are a number of cytokines, cell adhesion molecules, and acute phase proteins.

25 It is well-known that NF-kappaB plays a key role in the regulated expression of a large number of pro-inflammatory mediators including cytokines such as IL-6 and IL-8. Cell adhesion molecules, such as ICAM and VCAM, and inducible nitric oxide

synthase (iNOS). Such mediators are known to play a role in the recruitment of leukocytes at sites of inflammation and in the case of iNOS, may lead to organ destruction in some inflammatory and autoimmune diseases.

5 The importance of NF-kappaB in inflammatory disorders is further strengthened by studies of airway inflammation including asthma, in which NF-kappaB has been shown to be activated. This activation may underlie the increased cytokine production and leukocyte infiltration characteristic of these disorders. In addition, inhaled steroids are known to reduce airway hyperresponsiveness and suppress the 10 inflammatory response in asthmatic airways. In light of the recent findings with regard to glucocorticoid inhibition of NFkappaB, one may speculate that these effects are mediated through an inhibition of NFkappaB.

Further evidence for a role of NF-kappaB in inflammatory disorders comes from 15 studies of rheumatoid synovium. Although NF-kappaB is normally present as an inactive cytoplasmic complex, recent immunohistochemical studies have indicated that NF-kappaB is present in the nuclei, and hence active, in the cells comprising rheumatoid synovium. Furthermore, NF-kappaB has been shown to be activated in human synovial cells in response to stimulation with TNF-alpha. Such a distribution 20 may be the underlying mechanism for the increased cytokine and eicosanoid production characteristic of this tissue. See Roshak, A. K., et al., J. Biol. Chem., 271, 31496-31501 (1996).

Further evidence for a role of NF-kappaB in inflammatory disorders comes from 25 studies of rheumatoid synovium. Although NF-kappaB is normally present as an inactive cytoplasmic complex, recent immunohistochemical studies have indicated that NF-kappaB is present in the nuclei, and hence active, in the cells comprising

rheumatoid synovium. Furthermore, NF-kappaB has been shown to be activated in human synovial cells in response to stimulation with TNF-alpha. Such a distribution may be the underlying mechanism for the increased cytokine and eicosanoid production characteristic of this tissue. See Roshak, A. K., et al., J. Biol. Chem., 271, 5 31496-31501 (1996).

The NF-kappaB/Rel and IkappaB proteins are also likely to play a key role in neoplastic transformation. Family members are associated with cell transformation *in vitro* and *in vivo* as a result of over-expression, gene amplification, gene 10 rearrangements or translocations. In addition, rearrangement and/or amplification of the genes encoding these proteins are seen in 20-25% of certain human lymphoid tumors. In addition, a role for NF-kappaB in the regulation of apoptosis has been reported strengthening the role of this transcription factor in the control of cell proliferation.

15 The first plant-derived modulators of NF-kB were reported nearly a decade ago by Kopp & Ghosh (1994) who identified sodium salicylate and its semi-synthetic derivative, aspirin. Following this discovery, a number of new natural products, of different chemical classes, have demonstrated NF-kB inhibitory activity.

20 Several NF-kappaB inhibitors are described in the literature C. Wahl, et al. J. Clin. Invest. 101(5), 1163-1174 (1998), R. W. Sullivan, et al. J. Med. Chem. 41, 413-419 (1998), J. W. Pierce, et al. J. Biol. Chem. 272, 21096-21103 (1997). The marine natural product hymenialdisine is known to inhibit NF-kappa.B. Roshak, A., et al., 25 JPET, 283, 955-961 (1997). Breton, J. J and Chabot-Fletcher, M. C., JPET, 282, 459-466 (1997). Salicylanilides are known compounds and described by M. T. Clark, R. A. Coburn. R. T. Evans, R. J. Genco, J. Med. Chem., 1986, 29, 25-29.

Recently, an important mechanism of the inhibition of NF-kappaB suggest the possible activation of the receptors for peroxisomes.

The receptors for peroxysomes known as "Peroxisomes Proliferator Activated

5 Receptors" (PPARs), [attending to the usual use of the term, expressed in its abbreviation known in the scientific area, said abbreviation shall be used for identifying this receptor] have been implicated in autoimmune diseases and other diseases, i.e diabetes mellitus, cardiovascular and gastrointestinal disease, and Alzheimer's disease. The current pharmaceutical agents with PPAR gamma agonist 10 are still in the experimental stage and have significant side effects for human health, due to its mechanism of action. Therefore, there is the need to develop new agents with lesser toxic effects that can modulate these receptors more accurately in order to prevent, treat and/or alleviate the above mentioned diseases or conditions.

15 This new composition, modulates these receptors more accurately, and therefore allows preventing, treating and/or alleviating autoimmune diseases more efficiently, without causing undesirable side effects to the patients.

Peroxisomes Proliferator Activated Receptors (PPARs) are members of the nuclear

20 hormone receptor super family, which are ligand-activated transcription factors regulating gene expression. Various subtypes of PPARs have been discovered. These include PPARalpha, PPARbeta or NUC1, PPAR $\gamma$  and PPARdelta.

PPAR $\gamma$  was characterized originally as a key regulator of adipocyte differentiation and

25 lipid metabolism. PPAR $\gamma$  expression is directed by different promoters, leading to three PPAR $\gamma$  isoforms. It is now clear that PPAR $\gamma$  is also found in other cell types including fibroblasts, myocytes, breast cells, the white and red pulp of rat spleen,

human bone-marrow precursors, and macrophages/monocytes. In addition, PPAR $\gamma$  has been shown in macrophage foam cells in atherosclerotic plaques. An important role for PPAR $\gamma$  in glucose metabolism was identified when it was demonstrated that a class of antidiabetic drugs, the thiazolidinediones, were high-affinity PPAR $\gamma$  ligands.

5 The thiazolidinediones were developed originally for the treatment of type-2 diabetes on the basis of their ability to lower glucose levels (and levels of circulating fatty acids) in rodent models of insulin resistance. The finding that the thiazolidinediones mediate their therapeutic effects through direct interactions with PPAR $\gamma$  established PPAR $\gamma$  as a key regulator of glucose and lipid homeostasis. Despite being described 10 initially as a regulator of lipid and glucose metabolism, PPAR $\gamma$  has also been demonstrated recently to have a role in cell proliferation and malignancy. Ligands for PPAR $\gamma$  have been shown to mediate positive and negative effects on cell proliferation and malignancy.

15 In addition to the thiazolidinedione class of antidiabetic drugs, a variety of nonsteroidal anti-inflammatory drugs also can function as PPAR $\gamma$  ligands, although the latter have relatively low affinity.

20 The prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) dehydration product PGJ<sub>2</sub> was the first endogenous ligand discovered for PPAR $\gamma$ . The additional PGD<sub>2</sub> dehydration product, 15-deoxy- $\Delta^{12,14}$ -PGJ<sub>2</sub> (15d-PGJ<sub>2</sub>), is also a naturally occurring substance that binds directly to PPAR $\gamma$  and is a potent ligand for PPAR $\gamma$  activation.

25 One of the earliest findings associating PPARs and macrophages was that PPAR $\gamma$  was highly expressed in macrophage-derived foam cells of human and murine atherosclerotic lesions. Subsequently, it has been demonstrated that PPAR $\gamma$  is

expressed in human and murine monocytes/macrophages. Functionally, PPAR $\gamma$  has been shown to play a role in the differentiation and activation of monocytes and in the regulation of inflammatory activities.

- 5 Many studies have demonstrated that PPAR $\gamma$  ligands inhibit macrophage-inflammatory responses. The anti-inflammatory effects of PPAR $\gamma$  activation have been demonstrated with human and murine monocyte/macrophages and monocyte/macrophage lines. Activation of macrophages normally leads to the secretion of several different proinflammatory mediators. Treatment with 15d-PGJ<sub>2</sub> or 10 thiazolidinediones has been found to inhibit the secretion of many of these mediators (including gelatinase B, IL-6, TNF- $\alpha$ , and IL-1 $\beta$ ) and also to reduce the induced expression of inducible NOS (iNOS) and the transcription of the scavenger receptor-A gene.
- 15 The relevance of PPAR $\gamma$  has been studied in several human autoimmune diseases and animal models of autoimmune diseases. Kawahito et al. demonstrated that synovial tissue expressed PPAR $\gamma$  in patients with rheumatoid arthritis (RA). PPAR $\gamma$  was found to be highly expressed in macrophages, and modest expression was noted in synovial-lining fibroblasts and ECs. Activation of PPAR $\gamma$  by 15d-PGJ<sub>2</sub> and troglitazone 20 induced RA synoviocyte apoptosis *in vitro*.

It has been suggested that PPAR $\gamma$  is functionally relevant in freshly isolated T cells or becomes functionally relevant early in activation. In these studies, it was also demonstrated that the two ligands for PPAR $\gamma$  mediated inhibition of IL-2 secretion by 25 the T-cell clones and did not inhibit IL-2-induced proliferation of such clones.

Several studies have investigated the role of PPAR $\gamma$  ligands in modifying animal models of autoimmune diseases. Su et al. showed that in a mouse model of inflammatory bowel disease, thiazolidinediones markedly reduced colonic inflammation. It has been proposed that this effect might be a result of a direct effect 5 on colonic epithelial cells, which express high levels of PPAR $\gamma$  and can produce inflammatory cytokines. Kawahito et al. demonstrated that intraperitoneal administration of the PPAR ligands, 15d-PGJ<sub>2</sub> and troglitazone, ameliorated adjuvant-induced arthritis. Nino et al. examined the effect of a thiazolidinedione on 10 experimental allergic encephalomyelitis and found that this treatment attenuated the inflammation and decreased the clinical symptoms in this mouse model of multiple sclerosis. Finally, Reilly et al. demonstrated that renal glomerular mesangial cells are 15 important modulators of the inflammatory response in lupus nephritis, secreting, when activated, inflammatory mediators including NO and cyclooxygenase products, thus perpetuating the local inflammatory response. Given the above studies, the relevance of PPARs and the utility of treatment with PPAR agonists in diseases with an inflammatory or autoimmune pathogenesis will likely continue to remain a research focus.

Recently, the issue of the specificity of 15d-PGJ<sub>2</sub> for PPAR $\gamma$  has been at least partially 20 clarified. NF- $\kappa$ B is a critical activator of genes involved in inflammation and immunity. In this activation, the I $\kappa$ B kinase complex (IKK) phosphorylates the NF- $\kappa$ B inhibitors (I $\kappa$ B proteins) leading to their conjugation with ubiquitin and subsequent degradation by proteosome. This then allows freed NF- $\kappa$ B dimers to translocate to the 25 nucleus and induce target genes. Rossi et al. demonstrated that the cyclopentenone PGs, including 15d-PGJ<sub>2</sub>, directly inhibit and modify the IKK2 subunit of IKK. This, in turn, prevents the phosphorylation of the inhibitory I $\kappa$ B proteins that then target these proteins for ubiquitin conjugation and degradation. This then prevents the

activation of NF-κB. Similarly, Castrillo et al. showed that in RAW 264.7 macrophage cells treated with LPS and IFN- $\alpha$ , incubation with 15d-PGJ<sub>2</sub> resulted in a significant inhibition of IKK2 activity and an inhibition of the degradation of the inhibitory I $\kappa$ B proteins. This, in turn, caused a partial inhibition of NF-κB activity and an impaired expression of genes requiring NF-κB activation, such as type-2 NOS and cyclooxygenase 2.

Therefore, it can be concluded that PPAR $\gamma$  and NF-κB are important mediators involved in autoimmune diseases, resulting in a stimulus to the pharmaceutical industry to search for new selective drugs and medicines that affects these mediators.

On the other hand, Alzheimer's disease (AD) is characterized by the extracellular deposition of  $\beta$ -amyloid fibrils within the brain and the activation of microglial cells associated with the amyloid plaque. The activated microglia subsequently secretes a diverse range of inflammatory products. Kitamura et al. assessed the occurrence of PPAR $\gamma$  and COX-1, COX-2, in normal and AD brains using specific antibodies and found increased expression of these moieties in AD brains. Nonsteroidal, anti-inflammatory drugs (NSAIDs) have been shown to be efficacious in reducing the incidence and risk of AD and in delaying disease progression. Combs et al. demonstrated that NSAIDs, thiazolidinediones, and PGJ<sub>2</sub>, all of which are PPAR $\gamma$  agonists, inhibited the  $\beta$ -amyloid-stimulated secretion of inflammatory products by microglia and monocytes. PPAR $\gamma$  agonists were shown to inhibit the  $\beta$ -amyloid-stimulated expression of the genes for IL-6 and TNF- $\alpha$  and the expression of COX-2. Heneka et al. demonstrated that microinjection of LPS and IFN- $\alpha$  into rat cerebellum induced iNOS expression in cerebellar granule cells and subsequent cell death. Coinjection of PPAR $\gamma$  agonists (including troglitazone and 15d-PGJ<sub>2</sub>) reduced iNOS expression and cell death, whereas coinjection of a selective COX inhibitor had no

effect. Overall, work in AD seems to suggest that PPAR $\gamma$  agonists can modulate inflammatory responses in the brain and that NSAIDs may be helpful in AD as a result of their effect on PPAR $\gamma$ .

5 From the previously exposed herein, it can be concluded:

Till now, there are no antecedents of PPAR- $\gamma$  agonist compounds isolated from medicinal plants. Nowadays, there are no drugs, compositions or medicines with these properties for the treatment of autoimmune diseases.

10 Whereas, this new composition is able to reduce the pro-inflammatory cytokines production, that are increased in autoimmune and neurodegenerative diseases.

Additionally, the composition of the present invention has low toxicity, and does not exhibit any harmful side effects.

15 Given the current “State of Art” in Science, the use of said composition cannot be deduced by an expert in the field, wherein said composition is directed for the above mentioned diseases, with said properties, maintaining the immune tolerance, without causing adverse effects, as occurs with other substances that are currently used for these diseases.

20

*Andrographis paniculata* (Nees), is a medicinal plant pertaining to the Acanthaceae family native to Asia, India, Malaysia, China, Korea and elsewhere. In these countries it has been widely employed for their beneficial effects of the fresh and dried plant or its components in different diseases, such as common cold, liver conditions, diabetes,

25 etc.

## BRIEF DESCRIPTION OF THE FIGURES

Figure 1. Is a representative graph showing the PAF induced calcium displacement measured through the ratio 340/380 nm, using HL-60 cells marked with FURA2-AM indicator. The cells were differentiated with retinoic acid alone, or in presence with the composition of the present invention (3.5  $\mu$ g/mL), as described in examples 1-2, disclosed hereinafter.

Figure 2. Shows a bar diagram depicting the relative luciferase activity in HL-60 cells transfected with a vector that contains the promoter of PPAR $\gamma$  and the effect of the composition of the present invention.

Figure 3. Is a bar graph showing the inhibition of IL-2 and INF-gamma concentration in T cells activated with concanavalin CONA by the composition of the present invention.

Figure 4. Shows the inhibition of the  $\text{kB}\alpha$  degradation by the composition of the present invention and the bar diagram shows the inhibition percentage of the composition of the present invention on the relative luciferase activity in HL-60 cells transfected with a vector that contains the NF $\kappa$ B promotor.

Figure 5. Is a microphotography showing the *in vitro* inhibition of  $\beta$  amiloid formation by the composition of the present invention, using the thioflavin staining.

Figure 6. Illustrates the chemical structure of Andrographolide.

Figure 7. Illustrates the general chemical structure of 14-deoxyandrographolide.

Figure 8. Illustrates the chemical structure of Neoandrographolide.

## DETAILED DESCRIPTION OF THE INVENTION

5

In the present application, a new composition is described, that induces PPAR-gamma agonistic effects and inhibits the activation of the transcription factor NF-kappaB using a mixture of andrographolides extracted from *Andrographis paniculata* by applying the procedure disclosed herein.

10

## DESCRIPTION OF THE ANDROGRAPHOLIDES COMPOSITION

The composition claimed in the present application, comprises a mixture of diterpenic labdanes, obtained from an extract of *Andrographis paniculata* dried extract, having 15 the following general formulae:

$C_{20}H_{30}O_5$  Andrographolide

$C_{20}H_{30}O_4$  14-Deoxiandrographolide

$C_{26}H_{41}O_8$  Neoandrographolide

20

The chemical structure of these compounds is disclosed on figures 6, 7 and 8.

A representative extract of the present composition, is constituted by a mixture of the following Andrographolides: Andrographolide, 14-Deoxyandrographolide, and 25 Neoandrographolide. Wherein said individual components are contained approximately 20 to 40% w/w of Andrographolide, about 3 to 6% w/w of 14-Deoxyandrographolide, and about 0.2 to 0.8% w/w of Neoandrographolide in the

dried extract. Preferably these compounds are contained from about 25 to 35% w/w of Andrographolide, from about 4.5 to 5.5% w/w of 14-deoxyandrographolide, and approximately 0.4 to 0.8% w/w of Neoandrographolide in the final extract.

5 In a more preferred embodiment, the novel extract comprises:

Andrographolide	24.6%
14-Deoxyandrographolide	4.8%
Neoandrographolide	0.6%

10 Said formulation is acceptable for manufacturing medicines which can be administered with a pharmaceutically acceptable carrier, i.e. a tablet form, administered in a dose comprising approximately 1 to 6.5 mg/kg BW/day of the andrographolides mixture.

15

- a) 1 - 5 mg Andrographolide/kg per day
- b) 0.2 - 1 mg 14-Deoxiandrographolide/kg per day
- c) 0.02 - 0.12 mg NeoAndrographolide/ kg per day.

20 Without affecting other formulation and administration embodiments, those herein disclosed, contribute efficiently and effectively for the treatment of autoimmune diseases already mentioned and also for treating Alzheimer's disease, according to the following examples.

25 Therefore, both the composition and its pharmaceutical formulation particularly when administered in the tablet form and in the above indicated doses, provide a medicine for treating a variety of autoimmune diseases such as: inflammatory disorders;

particularly, diabetes mellitus, inflammatory bowel disease; autoimmune diseases (lupus erythematosus, multiple sclerosis and rheumatoid arthritis).

Due to its mechanism of action, the compounds and the pharmaceutical composition herein disclosed can also be useful for treating AIDS and tissue and organ rejection.

5

The pharmaceutical composition that can be manufactured with the herein disclosed composition, specially according to the revealed formulation, can correspond to enteral, parenteral, dermic, ocular, nasal, otic, rectal, vaginal, urethral, bucal, pharyngeal-tracheal-bronchial pharmaceutical forms.

10

#### METHOD OF OBTENTION AND ANALYSIS OF *ANDROGRAPHIS PANICULATA* RAW MATERIAL

Active ingredient: *Andrographis paniculata* Nees (Burm. f.)

15

Family: Acantaceae

Used part: herba

The green leaves, stems and higher parts, including the seeds are sun dried. All foreign materials are manually removed and the raw material is cut into 1-1.5 cm size 20 pieces, which are stored in a ventilated area. Routine analysis is carried out in order to asses the identity: macro and microscopic analysis, organoleptic parameters and TLC analysis (thin layer chromatography) is performed according to European Pharmacopoeia.

25

#### METHOD FOR OBTAINING THE *ANDROGRAPHIS PANICULATA* DRIED EXTRACT

The extraction of *A. paniculata* is performed by continuous percolation of the grinded dried plant (aerial part) using a hydroethanolic solution (70% ethanol/water).

5 The duly analyzed drug material is grinded to suitable particle size in a knife-hammer mill (0.8 cm<sup>2</sup>). The grinded material is charged into stainless steel percolators and the extraction solution is added at a temperature of 158°F (70°C). The percolation time is of approximately 6 days (6x24hours) in two extraction cycles. The percolate is collected in stainless steel tanks until the percolation is completed. The percolate is  
10 transferred directly to an evaporation unit in order to eliminate ethanol and most of the water. Evaporation is performed in a LUWA thin-film evaporator at 140–158°F (60-70°C) and 0.65-0.85 bar vacuum. The evaporation process is performed in 3-4 cycles, where the extract is kept under mixing, 4 times during 30 minutes per day. When the spissum extract has the right content of water, the following analysis are  
15 made: ash content, HCL-ash, loss on drying, pH value, TLC identity and HPLC (high performance liquid chromatography), analysis for Andrographolide, 14-Deoxiandrographolide and Neoandrographolide. Then the spissum extract is transferred to the drying unit. Before drying, the spissum extract is mixed with a suitable amount of maltodextrin as carrier and then dried by means of spray drying  
20 at an in-let temperature of 347-383°F (175-195° C) and an out-let temperature of 85-05°C. The final dried extract is packaged in plastic bags in fiber drums for subsequent analysis.

#### METHOD OF EXTRACTION AND STANDARIZATION IDENTITY of ANDROGRAPHIS PANICULATA – TLC

25 Test solution: To 1 g herbal extract, 20 ml of methanol is added, shaken for about 1 hour and the methanol is decanted through a filter. The residue is shaken with 20 ml methanol, filtered and mixed with the first extract (making 40ml of test solution).

Reference solutions: 1 Andrographolide (A), 14-Deoxiandrographolide (DA) and Neoandrographolide (NA), dissolved in methanol. 2. Reference-extract treated in the same way as the test-extract. 20-30 ul test solution is applied to a TLC-plate (silica gel GF254 as coating substance) and developed over a path of 15 cm using a mixture of 77 volumes of ethyl acetate, 15 volumes of methanol and 8 volumes of water (77:15:8). Subsequently, the plate is allowed to dry in air and examined under UV (254nm). The few dark spots of the chromatogram correspond to Andrographolide at a  $R_f$ : 0.65-0.7; 14-Deoxiandrographolide  $R_f$ : 0.75-0.8 and Neoandrographolide,  $R_f$ : 10 0.60-0.65.

#### HPLC METHOD FOR THE QUANTIFICATION OF DITERPENIC LABDANES

The three compounds are extracted with acetone (4:1) and then analyzed by HPLC 15 using a reverse phase RP-C18 licrospher column (4x125mm). The mobile phase consists of acetonitrile 26% and phosphoric acid 0.5%, at a rate of 1.1 ml/min, and is detected at 228 nm according to Burgos et al.; 1999, Acta Hort. (ISHS) 501:83-86.

The *Andrographis paniculata* dried extract is standardized to a minimum of 30% of 20 total Andrographolides, which comprises approximately 20 to 40% w/w of andrographolide, 3 to 6% w/w of 14-Deoxyandrographolide, and 0.2 to 0.8% w/w of Neoandrographolide.

The composition according to the present invention has not been previously disclosed 25 in the current “state of the art” in science and there are no antecedents about the use of the same in order to solve the described methodological problems concerning autoimmune diseases and AD.

The pharmaceutical compositions of this invention may be administered orally or parenterally, and the parenteral administration comprises intravenous injection, subcutaneous injection, intramuscular injection and intraarticular injection.

- 5 The correct dosage of the pharmaceutical compositions of the invention will vary depending on the particular formulation, the mode of application, age, body weight and gender of the patient, diet, disease status of the patient, complementary drugs and adverse reactions. It is understood that the ordinary skilled physician will readily be able to determine and prescribe a correct dosage of this pharmaceutical compositions.
- 10 Preferably, the daily dosage of this pharmaceutical compositions ranges from 1- 6.5 mg of the andrographolides mixture per kg body weight.

According to the conventional techniques known to those skilled in the art, the pharmaceutical compositions of this invention can be formulated with a

- 15 pharmaceutical acceptable carrier and/or vehicle as described above, such as a unit dosage form. Non-limiting examples of the formulations include, but not limited to, a sterile solution, a solution, a suspension or an emulsion, an extract, an elixir, a powder, a granule, a tablet, a capsule, a liniment, a lotion and an ointment.
- 20 The present invention also embraces the pharmaceutical compositions containing Andrographolide, 14-Deoxiandrographolide and Neoandrographolide Labdanes compounds in combination with pharmaceutically acceptable carriers normally employed in preparing such compositions.
- 25 In the pharmaceutical compositions of this invention, the pharmaceutically acceptable carrier may be any conventional one described for pharmaceutical formulations, such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium

phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, Hydroxypropylmethylcellulose (HPMC), methylhydroxy benzoate, propylhydroxy benzoate, talc, stearic acid, magnesium and mineral oil, but not limited thereto.

5 Additionally, the pharmaceutical compositions of the present invention may contain any of a wetting agent, sweetening agent, emulsifying agent, suspending agent, preservatives, flavors, perfumes, lubricating agent, or mixtures of these substances.

Typically, the pharmaceutical compositions contains from 20-40 %, preferably from 10 25 to 35%, and most preferably 30% w/w of andrographolide , 14-Deoxiandrographolide and Neoandrographolide Labdanes of the mixture, and the pharmaceutically acceptable carriers.

The pharmaceutical composition of the present invention can be administered to 15 mammals in need thereof, via oral route administered singly or as a divided dose.

Thus, for oral administration, the compounds can be combined with a suitable solid carrier to form capsules, tablets, powders. Additionally, the pharmaceutical compositions may contain other components such as flavourants, sweeteners, excipients and the like.

20

Additionally, the present invention provides a method for treating patients with the composition containing the andrographolides mixtures which comprises: intravenous administering of the solution and orally administering the tablets comprising the composition of the present invention to patients in need thereof. The preferred dosage 25 of the injection solution formulation is about 60 to 210 mg/day, most preferably, 60-80 mg/day, of the composition per day in one, two or three injections.

The present formulation in the injectable solution form comprises 8-16 mg approximately of the composition per ml. When administering to patients, the composition is preferably diluted to about 1:5 to 1:10 volume of 0.9% saline solution.

5 The following examples are illustrative, but do not limit the scope of the present invention. Reasonable variations, such as those occurring to a reasonable artisan, can be made herein without departing from the scope of the present invention.

10 The pharmaceutical composition of the present invention is suitable for preparation in a scale typical for pharmaceutical industry as well as for smaller measure. Following conventional techniques of the pharmaceutical industry involving wet granulation, dry granulation, direct compression, fluid bed granulation, when necessary, for tablet forms, as appropriate, to give the desired oral, or parenteral products.

15 The percentages indicated in the following examples are all given by weight.

#### EXAMPLES

Exemplary of a typical method for preparing a tablet containing the active agents is to 20 first mix the agent with a binder such as gelatin, ethyl cellulose, or the like. Wherein the mixing is suitably carried out in a standard V-blender and usually under anhydrous conditions. Next, the just prepared mixture can be slugged through conventional tablet machines and the slugs fabricated into tablets. The freshly prepared tablets are coated, with suitable coatings including shellac, methylcellulose, 25 carnauba wax, styrene-maleic acid copolymers, and the like.

For oral administration, the compressed tablets containing from 30 mg up to 40 mg of the andrographolide mixture are manufactured according to the above disclosed methods of manufacturing techniques well known to the art and set forth in Remington's Pharmaceutical Science, Chapter 39, Mack Publishing Co., 1965.

5

The preferred pharmaceutical compositions of the present invention formulations are shown in some of the following Examples.

EXAMPLE 1

10 Pharmaceutical composition for preparing a tablet of the present invention, using the andrographolide mixture contained in the dried extract obtained from the herb *Andrographis paniculata* Nees.

---

	Ingredients: Per tablet	mg.
15		
	Dried Extract (Andrographolides mixture)	135.0
	Potato starch	168.8
	Talc	106.9
	Gelatin	11.5
20	Magnesium stearate	5.6
	Hydroxypropylmethyl cellulose	3.5
	Silicon dioxide, anhydrous	2.0
	Polyethylenglycol	0.7
	Carbonate, calcium (qsp.)	16

25

---

To formulate the tablet uniformly blend the dried extract (Andrographolides mixture) active compound, potato starch, talc, gelatin, hydroxypropylmethylcellulose, silicon dioxide, anhydrous, polyethylene glycol, and calcium carbonate under dry conditions in a conventional V-blender until all the ingredients are uniformly mixed. The mixture 5 is then passed through a standard light mesh screen, dried in an anhydrous atmosphere and then blended with magnesium stearate, and compressed into tablets, and coated with shellac. Other tablets containing from 116 to 162 mg, are prepared in a similar fashion.

10 EXAMPLE 2

Pharmaceutical composition for preparing a capsule of the present invention, using the dried extract obtained from the herb *Andrographis paniculata* Nees.

---

15	Ingredients: Per capsule	mg.
	Dry Extract, (Andrographolides mixture)	135.0
	Potato starch	168.8
	Talc	106.9
	Gelatin	11.5
20	Magnesium stearate	5.6
	Hydroxypropylmethyl cellulose	3.5
	Silicon dioxide, anhydrous	2.0
	Polyethylen Glycol	0.7
	Carbonate, calcium	16
25		

---

The manufacture of capsules containing from 30 mg to 40 mg of andrographolide mixture for oral use consists essentially of mixing the Dried Extract, (Andrographolides mixture) with a carrier and enclosing the mixture in a polymeric sheath, usually gelatin or the like. The capsules can be in the art known soft form of a 5 capsule made by enclosing the compound in intimate dispersion within an edible, compatible carrier, or the capsule can be a hard capsule consisting essentially of the novel compound mixed with a nontoxic solid such as talc, calcium stearate, calcium carbonate, or the like. Exemplary of a typical use for employing a capsule containing 30mg of 40mg for use as therapeutically indicated.

10

The dose administered, whether a single dose, multiple dose, or a daily dose, will of course, vary with the particular compound of the invention employed because of the varying potency of the compound, the chosen route of administration, the size of the patient and the nature of the disease condition. The administered dose corresponds to 15 a general oral dose of 80 to 160 mg daily, with the oral dose of normally 120 mg three times per day; the usual intravenous dose of 60 to 80 mg, followed if indicated by 70 to 100 mg at a later period, and the usual intramuscular dose of 70 to 100 mg every 24 hours, with 1 to 2 injections per day.

20 The novel and useful pharmaceutical compositions comprising the Dried Extract, (containing a Andrographolides mixture) of the invention are adaptable for the administration for their physiological expected effects from drug delivery systems, such as skin delivery systems, gastrointestinal drug delivery devices, and the like, wherein the delivery device is manufactured from naturally occurring and synthetic 25 polymeric materials. Representative of materials acceptable for the fabrication of drug delivery systems containing the compounds for controlled drug administration include materials such as polyvinyl chloride, polyisoprene, polybutadiene, polyethylene,

ethylene-vinyl acetate copolymers, polydimethylsiloxane, hydrophilic hydrogels of esters of acrylic and methacrylic acid, polyvinyl acetates, propylenevinyl acetate copolymers, and the like.

5 EXAMPLE N°3

Shellac covered tablets containing the above indicated composition are prepared following conventional techniques of the pharmaceutical industry involving mixing, granulating, and compressing, when necessary, for tablet forms.

10 Specifically the composition of example 1 is thoroughly mixed with a sufficient amount of *Andrographis paniculata* dried extract. For the manufacture of tablets comprising Andrographolide, 14-Deoxiandrographolide and Neoandrographolide, the mixture is compressed in a direct form with the inactive ingredients mentioned in example N°1, and subsequently covered with shellac, accordingly.

15

EXAMPLE N°4

HL-60 cell differentiation induced by the composition.

20 Chemicals: May Grunwald-Giemsa, NBT, retinoic acid, cytochalasin B, penicillin, streptomycin, glutamine, fetal bovine serum (Sigma). RPMI 1640 (GIBCO), Fetal bovine serum from Boehringer Mannheim, all trans-retinoic acid and andrographolide was from Aldrich. The other isolates were supplied from Amsar Pvt. Ltd., India. FURA2-AM was purchased from Molecular Probes (USA). Nitroblue tetrazolium was from Sigma.

25

Cell Culture: *HL* 60 cells were grown in RPMI 1640 medium supplemented with 20% heat-inactivated fetal bovine serum, 2 mM glutamine, 100 IU/ml penicillin, and 100

pg/ml streptomycin at 37 °C in a humidified atmosphere containing 5%  $CO_2$ . Cells were seeded twice weekly at  $3 \times 10^5$  cells/ml. Differentiation was induced by adding 100 nM of all-trans-retinoic acid, alone or combined with the composition (17.5  $\mu$ g/ml) and assessed by the change in morphology after May Grunwald-Giemsa staining and the ability to reduce NBT' (11). Undifferentiated cultures contained less than 3% NBT positive cells. Differentiated cultures were studied after 5 days of retinoic acid treatment.

#### Calcium Measurement [Ca<sup>2+</sup>]c

10 HL-60 granulocytes ( $2 \times 10^7$ /ml) were loaded with 2  $\mu$ M fura-2/AM in Ca<sup>2+</sup> medium plus 0.1% bovine serum albumin for 45 min at 37 °C, then diluted to  $10^7$  cells/ml and kept on ice. Just before use, 0.5 ml of this cell suspension was centrifuged and resuspended in 2.4 ml of the indicated medium including 5  $\mu$ g/ml cytochalasin B. Fura-2 fluorescence ( $F$ ) was measured in a thermostated cuvette (37 °C) (LS55 15 fluorimeter, Perkin-Elmer Corp.) at 340 and 380 -nm excitation and 505-nm emission wavelength.

#### EXAMPLE N° 5

##### Inhibition of IL-2 and IFN- $\gamma$ production in T cells by the composition.

20 Chemicals: concanavaline A and RPMI 1640 medium from Sigma.

Cell cultures: Rockefeller mice were sacrificed by ether and the popliteal ganglia and spleen were placed in a Petri plaque containing 5 ml of a medium culture RPMI 1640. 25 The lymph cells were obtained by disrupting these organs in a RPMI 1640 sterile solution, and the lymphocytes were re-suspended in 1 ml of RPMI 1640 medium and quantified with a Neubauer chamber. Finally, the suspension of lymphocytes was

adjusted to a concentration of  $4 \times 10^6$  cells per ml RPMI. Once obtained, the lymphocytes were cultivated in presence or absence of the composition. For this purpose, culture plaques of polystyrene of 24 well (2 ml each); containing 1 ml cells and different concentrations of the composition and 1 ml of the mitogen 5 concanavaline A (CONA, 0  $\mu$ g/ml and 10  $\mu$ g/ml) were used.

The plaques were incubated in a oven at 37° C in an atmosphere of humidity 5% and CO<sub>2</sub> for 24h, then a sample of 2 ml each were added and centrifuged for one minute at 3200 rpm. Afterwards, the cells were freezed in 0, 6 ml aliquots and the cytokines 10 detected with ELISA (Enzyme Linked Immuno Sorbent Assay).

#### ELISA for IL-2 and IFN- $\gamma$

Chemicals: IL-2 & IFN gamma from Pharmingen; TMB from Pierce, H<sub>2</sub>O<sub>2</sub> and H<sub>2</sub>SO<sub>4</sub> from Merck.

15 For the determination of cytokines (IL-2 and IFN) a first antibody that captures the anti-antigen; a second antibody that conjugates to a peroxidase enzyme and a standard solution for a calibration curve was used. ELISA "high binding" plaques of polystyrene with 96 wells were used. 100  $\mu$ l per web of the first antibody was diluted in carbonate buffer pH 9.5 with the aim to facilitate the sticking to the well, and 20 incubated overnight at 4° C to assure the union to the solid part. Afterwards, the content of the well was eliminated and washed with 300  $\mu$ l per web with Tween 20; 0, 05 % p/v and PBS pH 7.0 three times. Then, the well was blocked with 200  $\mu$ l of fat free milk 5% and PBS, and incubated for 1 hour at room temperature. After completion, the content well was eliminated and washed as explained already. Then, 25 the test samples where added containing the antigen, 100  $\mu$ l per web in duplicate, and 100  $\mu$ l of a calibration curve specific for the cytokine and incubated for 2 hours at room temperature. Afterwards, the content well was eliminated and washed 5 times

according to the latter protocol. Then, the second conjugated antibody was added with the peroxidase enzyme and diluted in a PBS and SBF solution 10%, and 100  $\mu$ l was plated per well and left at room temperature for one hour. Then, washed 7 times and revealed with a solution of TMB and  $H_2O_2$ , 100  $\mu$ l per well and developed after 30 minutes in dark, the reaction stopped with  $H_2SO_4$  2M; 50  $\mu$ l per well. The result of the reaction was measured by ELISA with a 450  $\eta$ m filter (Elx800 universal Microplate Reader, BioteK).

#### EXAMPLE N°6

##### 10 Stimulation of PPAR- $\gamma$ receptor by the COMPOSITION

Chemicals: Dimethylsulfoxide purchased from Merck. All other reagents were purchased from PROMEGA.

Transcription Assays: HL-60 cells were transfected with pCMX-hPPAR $\gamma$ 1, the human PPAR $\gamma$ 1 expression vector under control of a cytomegalovirus promoter. Luciferase and  $\beta$ -galactosidase activities were determined; and the luciferase activity was normalized to the  $\beta$ -galactosidase standard in HL-60.

Plasmids: The plasmid expressing the GAL4-DNA binding domain (DBD) and the mPPAR $\gamma$  ligand binding domain (pGAL4DBD-mPPAR $\gamma$ ) was constructed by inserting the mouse PPAR $\gamma$ 1 ligand binding domain (from amino acids 162-475), isolated as a ScaI/BamHI fragment from pGBTmPPAR $\gamma$ 1 in-frame into pCMXGal4 DBD.

25 The cells were treated with DMSO or 17.5  $\mu$ g/ml composition of the present invention, and the luciferase activity was measured by chemiluminescence.

#### EXAMPLE N°7

## NF-κB inhibition in neutrophils by the composition

Chemicals: dimetilsulfoxide (DMSO) from Merck; bovine fetal serum and RPMI-1640 medium from Gibco, USA; nitro tetrazolium blue from Sigma, pRL-TK, pGL3 and Dual-Luciferase Reporter Assay System (Promega); Fugene6 from Roche;

### Cell culture

A cellular myeloid HL-60 line from acute myeloid leukemia was used. This cells can 10 differentiate in the presence of dimethylsulfoxide 1.3% (DMSO) (Santos-Benit *et al.*, 2000). The cells are kept in RPMI-1640 medium supplemented with 2 mM L-glutamine, 10% of bovine fetal serum inactivated by temperature and antibiotics with 5% CO<sub>2</sub> at 37° C. The cells are differentiated to neutrophils by incubating the 15 neutrophils with 1.3% of DMSO for 4 days. The differentiated cells are analyzed with nitro tetrazolium blue (NBT).

### Transfection of the NFkB-pGL3 vector in HL-60 cells and luciferase measurement

HL-60 cells were cultivated and differentiated to neutrophils for 4 days, as described 20 elsewhere. At day 4, the cells were transfected with the pGL3-NFkB vectors and as an internal control of the transfection a pRL-TK (Promega) vector was used, which is an expression vector that contains a promoter of thymidine kinase of the herpes simplex virus that allows the expression of moderate levels of *Renilla* luciferase. These vectors are transfected to the cells by a system based on liposomes (Fugene6, Roche). 25 Once the transfection is done, the cells are kept for 24 h, and then stimulated by PAF or fMLP at different times, in presence or absence of the composition of the present invention. Then, cellular extracts are kept at -70° C till the measurement of the

activity of luciferase. The activity of luciferase is measured by chemiluminescence, with the commercial system Dual-Luciferase Reporter Assay System (Promega) that possesses the substrates of the enzymes firefly (pGL3) and *Renilla* (pRL) luciferase.

5 I<sub>K</sub>B<sub>α</sub> Immunoblot

Chemicals: fMLP; PMSF and PAF were purchased from Calbiochem. Tris, NaCl, NP-40, deoxicolate, sodium dodecilsulphate, iprotease inhibitors, mercaptoethanol from Merck.

10 The neutrophils were preincubated for 10 minutes, and then stimulated with fMLP (0.1 uM) and PAF (0.1  $\mu$ M) for 60 min. For the analysis of proteins, the cells were lysed in a lysis tampon (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxicolate, 0.1% sodium dodecilsulfate, 1mM Na<sub>2</sub>VO<sub>4</sub>, 1mM PMSF and 10  $\mu$ g/ml de iprotease inhibitors). The proteins were quantified by the method of Bradford, 15 resolved by electrophoresis in poliacrilamide gel in denaturized conditions (SDS/PAGE) 12%, and electro transferred to a nitrocellulose membrane. The membrane was incubated with anti-I<sub>K</sub>B<sub>α</sub> antibodies for, followed by a secondary conjugated antibody to peroxides and finally visualized with chemiluminescence (ECL). As a control of the quantity of proteins in the gel, the antibodies were treated 20 with *stripping* solution (100 mM 2-mercaptopetanol, 2 % SDS, 62.5 mM Tris-HCl, pH 6.7) and incubated with an antibody anti-actin. Finally, a densitometric analysis with the obtained signals for each antibody was performed.

EXAMPLE N°8

25 Inhibition of  $\beta$ -amyloid formation by the composition in wild type rats

## Amyloid formation

To check the amyloid formation two complementary techniques, thioflavine-T fluorescence (Levine, 1993; Soto *et al.*, 1995; Reyes *et al.*, 1997, Inestrosa *et al.*, 2000) and Congo red binding (Alvarez *et al.*, 1998) were used. Briefly, the assay of 5 thioflavine-T is based on fluorescence emission of thioflavin when it binds to amyloid fibrils, showing an increasing of emission at 482 nm when is excited at 450 nm. The Congo red assay is a very specific quantification assay to determine the amount of amyloid formed. These techniques are currently used to verify the specific amyloid formation.

10

## EXAMPLE 9

### Description of a compound from the composition of Andrographolides

A representative composition of the present invention is a pharmaceutical formulation 15 in tablets, which supplies the following mixture of compounds:

Andrographolide 24.6%,

14-Deoxyandrographolide 4.8%

Neoandrographolide 0.6%

20

for the subsequent manufacture of the different pharmaceutical forms, and applied in the following doses:

a) 1-5 mg andrographolide/kg per day

25 b) 0.2 – 1 mg 14-Deoxiandrographolide/kg per day

c) 0.02-0.12 mg neoandrographolide/kg per day.

The chemical structure of these compounds is respectively depicted in figures 6, 7 and 8.

EXAMPLE N°10

5 Clinical efficacy of an oral formulation for the treatment of lupus erythematosus

Using the mixture of andrographolides described in example 7, a normalization of the symptoms due to lupus occurs following 3 months of administration. In addition, the composition does not interfere with the normal rebuilding effects of other traditional 10 non-steroidal anti-inflammatory agents.

EXAMPLE N°11

Clinical efficacy of an oral formulation for the treatment of multiple sclerosis

15 Using the mixture of andrographolides described in example 7, normalization in the symptoms of the disease occurs following 3 months of treatment of the COMPOSITION. In addition, the composition does not interfere with other treatments.

20 EXAMPLE N°12

Clinical efficacy of an oral formulation for the treatment of arthrosis and rheumatoid arthritis

Using the mixture of andrographolides described in example 7, normalization of joint 25 stiffness due to osteoarthritis occurs following 3 months, in the presence or absence of glucosamine or chrodoitin sulfate or other anti-inflammatory drugs. In addition, the

composition does not interfere with the normal joint rebuilding effects of these two proteoglycan constituents, unlike traditional non-steroidal anti-inflammatory

EXAMPLE N°13

5 Clinical efficacy of an oral formulation for the treatment of Diabetes mellitus

Using the mixture of andrographolides described in example 7, normalization in the sugar levels occurs following five weeks. In addition, the composition does not interfere with the normal rebuilding effects of other sugar reducing agents.

10

EXAMPLE N°14

Clinical efficacy of an oral formulation for treating AIDS

An oral formulation as described in Example 7 is administered to patients who are  
15 HIV positive. Normal CD4 counting is restored within 3 months of treatment.

EXAMPLE N°15

Clinical efficacy of an oral formulation for treating Alzheimer's disease

20 An oral formulation as described in Example 7 is administered to patients who have manifested an early stage of Alzheimer's Disease (AD), as diagnosed by their practitioner and confirmed by an independent board-certified neurologist. Two weeks before the clinical trial, the patients undergo appropriate psychoneurological tests such as the Mini Mental Status Exam (MMSE), the Alzheimer Disease Assessment  
25 Scale (ADAS), the Boston Naming Test (BNT), and the Token Test (TT).

Neuropsychological tests are repeated on Day 0, 6 weeks and 3 months of the clinical trial. The tests are performed by neuropsychologists who are not aware of the patient's treatment regimen.

- 5 Patients are randomly assigned to the test formulation or placebo at the start of the study. The test formulation and placebo are taken orally one or two times per day. Treatment for conditions such as diabetes, hypertension, etc. is allowed during the study. Scores are statistically compared between the test formulation and the placebo for each of the three observational periods. Without treatment, the natural course of
- 10 AD is significant deterioration in the test scores during the course of the clinical trial. Patients treated with the composition as described in the formulation are considered improved if the patients' scores remain the same or improve during the course of the clinical trial.
- 15 The patients shall receive randomly the composition or a placebo at the beginning of the study. The composition and placebo are administered twice a day. During the study the patients are allowed to be treated for conditions as diabetes, hypertension, etc.. The composition and placebo results are statistically compared for all the study periods. Patients using placebo show a significant cognitive deterioration. The
- 20 patients treated with the composition ameliorate in a considerable way the test scores.

From the foregoing description, it is obvious that one of ordinary skill in the art can not easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and/or modifications to the invention for adapting it to various usages and conditions. As such, these changes and modifications are properly, equitably and intended to be, within the full range of equivalence of the following claims.